keyword
MENU ▼
Read by QxMD icon Read
search

cetuximab AND radiotherapy

keyword
https://www.readbyqxmd.com/read/28198410/evaluation-of-the-immunological-profile-of-antibody-functionalized-metal-filled-single-walled-carbon-nanocapsules-for-targeted-radiotherapy
#1
Aritz Perez Ruiz de Garibay, Cinzia Spinato, Rebecca Klippstein, Maxime Bourgognon, Markus Martincic, Elzbieta Pach, Belén Ballesteros, Cécilia Ménard-Moyon, Khuloud T Al-Jamal, Gerard Tobias, Alberto Bianco
This study investigates the immune responses induced by metal-filled single-walled carbon nanotubes (SWCNT) under in vitro, ex vivo and in vivo settings. Either empty amino-functionalized CNTs [SWCNT-NH2 (1)] or samarium chloride-filled amino-functionalized CNTs with [SmCl3@SWCNT-mAb (3)] or without [SmCl3@SWCNT-NH2 (2)] Cetuximab functionalization were tested. Conjugates were added to RAW 264.7 or PBMC cells in a range of 1 μg/ml to 100 μg/ml for 24 h. Cell viability and IL-6/TNFα production were determined by flow cytometry and ELISA...
February 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28197666/elevated-basal-antibody-dependent-cell-mediated-cytotoxicity-adcc-and-high-epidermal-growth-factor-receptor-egfr-expression-predict-favourable-outcome-in-patients-with-locally-advanced-head-and-neck-cancer-treated-with-cetuximab-and-radiotherapy
#2
Laura Lattanzio, Nerina Denaro, Daniela Vivenza, Chiara Varamo, Giuliana Strola, Mirella Fortunato, Emmanuel Chamorey, Alberto Comino, Martino Monteverde, Cristiana Lo Nigro, Gerard Milano, Marco Merlano
BACKGROUND: Antibody-dependent cell-mediated cytotoxicity (ADCC) may contribute to the antitumor activity of cetuximab. However, the extent of this contribution is unclear. In this study, we investigated the impact of baseline ADCC on the outcome of patients with locally advanced squamous cell carcinoma treated with cetuximab and radiotherapy. METHODS: We determined baseline ADCC in 28 patients treated with cetuximab and radiotherapy and in 15 patients treated with chemoradiation...
February 14, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28196063/long-term-results-and-recurrence-patterns-from-scope-1-a-phase-ii-iii-randomised-trial-of-definitive-chemoradiotherapy-cetuximab-in-oesophageal-cancer
#3
T Crosby, C N Hurt, S Falk, S Gollins, J Staffurth, R Ray, J A Bridgewater, J I Geh, D Cunningham, J Blazeby, R Roy, T Maughan, G Griffiths, S Mukherjee
BACKGROUND: The SCOPE-1 study tested the role of adding cetuximab to conventional definitive chemoradiotherapy (dCRT), and demonstrated greater toxicity and worse survival outcomes. We present the long-term outcomes and patterns of recurrence. METHODS: SCOPE-1 was a phase II/III trial in which patients were randomised to cisplatin 60 mg m(-2) (day 1) and capecitabine 625 mg m(-2) bd (days 1-21) for four cycles +/- cetuximab 400 mg m(-2) day 1 then by 250 mg m(-2) weekly...
February 14, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28138221/immunotherapy-for-the-treatment-of-colorectal-tumors-focus-on-approved-and-in-clinical-trial-monoclonal-antibodies
#4
REVIEW
Alex Françoso, Patricia Ucelli Simioni
Colorectal cancer is considered a disease of the elderly population. Since the number of geriatric patients continues to rise, monoclonal antibody therapy is the most promising therapy in the recent research. Presently, the monoclonal antibodies most frequently used in the treatment of colorectal tumors are bevacizumab, cetuximab, panitumumab, and ramucirumab. Bevacizumab is a monoclonal antibody that acts on VEGF. Cetuximab and panitumumab act on EGFR. Ramucirumab binds directly to the ligand-binding pocket of VEGFR-2 to block the binding of VEGF-A, VEGF-C, and VEGF-D...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28138028/combining-chk1-2-inhibition-with-cetuximab-and-radiation-enhances-in-vitro-and-in-vivo-cytotoxicity-in-head-and-neck-squamous-cell-carcinoma
#5
Ling Zeng, Reena R Beggs, Tiffiny S Cooper, Alice N Weaver, Eddy S Yang
EGFR inhibition and radiotherapy are potent inducers of DNA damage. Checkpoint kinases 1 and 2 (Chk1/2) are critical regulators of the DNA damage response, controlling cell cycle checkpoints which may permit recovery from therapy-associated genomic stress. We hypothesized that Chk1/2 inhibition (CHKi) with prexasertib may enhance cytotoxicity from EGFR inhibition plus radiotherapy in head and neck squamous cell carcinoma (HNSCC). In this study, we found that the addition of CHKi to the EGFR inhibitor cetuximab with and without radiotherapy significantly decreased cell proliferation and survival fraction in HPV positive and HPV negative HNSCC cell lines...
January 30, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28134662/chemotherapy-for-localized-head-and-neck-squamous-cell-cancers
#6
Andy Karabajakian, Philippe Toussaint, Eve-Marie Neidhardt, Valérie Paulus, Pierre Saintigny, Jérôme Fayette
Concomitant chemotherapy with cisplatin (100 mg/m every 3 weeks) improves outcome for high-risk patients in the postoperative setting and for inoperable disease. Toxicity is increased. Other schemes of potentiation are sometimes used to reduce toxicity, but efficiency is diminished. Cetuximab also improves outcome, but there has been no direct comparison with cisplatin. Immunotherapy is currently being evaluated in association with radiation therapy. Trials are ongoing to evaluate the impact of de-escalation for human papillomavirus-positive patients...
January 27, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28125819/advanced-squamous-cell-carcinoma-of-the-head-and-neck-the-current-role-of-cetuximab
#7
Martín Granados-García, José Luis Aguilar-Ponce, Federico Maldonado-Magos, Jaime G De la Garza-Salazar
We review clinical trials of squamous cell carcinoma of the head and neck (SCCHN) to address the current and potential uses of cetuximab (CTX). PubMed was reviewed to identify papers published between 2010 and 2016. The search terms used were "cetuximab" and "head and neck cancer." A total of 634 articles were identified. Phase II or III studies with CTX in patients with advanced SCCHN without treatment or with recurrent/metastatic tumors were selected. Forty-six registries were obtained. Information was critically reviewed and relevant information presented...
January 27, 2017: ORL; Journal for Oto-rhino-laryngology and its related Specialties
https://www.readbyqxmd.com/read/28056412/toxicity-of-concurrent-stereotactic-radiotherapy-and-targeted-therapy-or-immunotherapy-a-systematic-review
#8
REVIEW
Stephanie G C Kroeze, Corinna Fritz, Morten Hoyer, Simon S Lo, Umberto Ricardi, Arjun Sahgal, Rolf Stahel, Roger Stupp, Matthias Guckenberger
BACKGROUND AND PURPOSE: Both stereotactic radiotherapy (SRT) and immune- or targeted therapy play an increasingly important role in personalized treatment of metastatic disease. Concurrent application of both therapies is rapidly expanding in daily clinical practice. In this systematic review we summarize severe toxicity observed after concurrent treatment. MATERIAL AND METHODS: PubMed and EMBASE databases were searched for English literature published up to April 2016 using keywords "radiosurgery", "local ablative therapy", "gamma knife" and "stereotactic", combined with "bevacizumab", "cetuximab", "crizotinib", "erlotinib", "gefitinib", "ipilimumab", "lapatinib", "sorafenib", "sunitinib", "trastuzumab", "vemurafenib", "PLX4032", "panitumumab", "nivolumab", "pembrolizumab", "alectinib", "ceritinib", "dabrafenib", "trametinib", "BRAF", "TKI", "MEK", "PD1", "EGFR", "CTLA-4" or "ALK"...
February 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28033526/induction-chemotherapy%C3%A2-followed-by-radiotherapy-for-larynx-preservation-in-advanced-laryngeal-and-hypopharyngeal-cancer-outcome-prediction-after-one-cycle-induction-chemotherapy-by-a-score-based-on-clinical-evaluation-computed-tomography-based-volumetry%C3%A2-and
#9
Gunnar Wichmann, Anne Krüger, Andreas Boehm, Marlen Kolb, Mathias Hofer, Milos Fischer, Stefan Müller, Sandra Purz, Patrick Stumpp, Osama Sabri, Andreas Dietz, Regine Kluge
BACKGROUND: Long-term laryngectomy-free (LFS), tumour-specific (TSS) and overall survival (OS) is achieved by non-surgical larynx preservation (LP) only in a proportion of patients with locally advanced laryngeal or hypopharyngeal cancer. A score facilitating decision-making after 1 cycle induction chemotherapy (IC-1) may improve LFS and TSS. METHODS: Early response to IC-1 with TPF ± cetuximab was assessed in 52 patients using endoscopic tumour staging for selecting total laryngectomy for non-responders with endoscopic tumour surface shrinkage <30% versus induction chemotherapy plus radiotherapy (IC + RT) for responders...
December 26, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/28032952/clinical-outcome-of-salvage-neck-dissections-in-head-and-neck-cancer-in-relation-to-initial-treatment-extent-of-surgery-and-patient-factors
#10
Karlijn van den Bovenkamp, Maartje G Noordhuis, Sjoukje F Oosting, Bernard F A M van der Laan, Jan L Roodenburg, Hendrik P Bijl, György B Halmos, Boudewijn E C Plaat
OBJECTIVE: Salvage surgery has a higher complication rate compared to primary surgical treatment. We evaluated clinical outcome of salvage neck dissections in relation to initial treatment modality, extent of surgery, and patient related factors. DESIGN: Single institution consecutive case series. SETTING: Tertiary Head and Neck Cancer Center. PARTICIPANTS: Eighty-seven patients with head and neck squamous cell carcinoma, who underwent salvage neck dissection after initial radiotherapy (n=30), radiotherapy with carboplatin/5-fluorouracil (n=43), or radiotherapy with cetuximab (n=14)...
December 29, 2016: Clinical Otolaryngology
https://www.readbyqxmd.com/read/28032719/minichromosome-maintenance-protein-7-and-geminin-expression-prognostic-value-in-laryngeal-squamous-cell-carcinoma-in-patients-treated-with-radiotherapy-and-cetuximab
#11
Giovanni Almadori, Libero Lauriola, Antonella Coli, Francesco Bussu, Roberto Gallus, Domenico Scannone, Vincenzo Valentini, Gaetano Paludetti, Thomas E Carey, Franco O Ranelletti
BACKGROUND: Minichromosome maintenance protein 7 (MCM7) is a downstream of human epidermal growth receptor (HER1) signaling. We examined MCM7, geminin, and HER1 expression in patients with laryngeal squamous cell carcinoma (SCC) treated with radiotherapy and cetuximab. METHODS: MCM7, geminin, and HER1 were evaluated by immunohistochemistry on 61 patients with laryngeal SCC. The follow-up (median, 32.1 months; range, 2-139 months) went from the beginning of therapy to tumor progression-free survival (PFS) and death (overall survival [OS])...
December 29, 2016: Head & Neck
https://www.readbyqxmd.com/read/28006059/the-kras-variant-and-cetuximab-response-in-head-and-neck-squamous-cell-cancer-a-secondary-analysis-of-a-randomized-clinical-trial
#12
Joanne B Weidhaas, Jonathan Harris, Dörthe Schaue, Allen M Chen, Robert Chin, Rita Axelrod, Adel K El-Naggar, Anurag K Singh, Thomas J Galloway, David Raben, Dian Wang, Chance Matthiesen, Vilija N Avizonis, Rafael R Manon, Omar Yumen, Phuc Felix Nguyen-Tan, Andy Trotti, Heath Skinner, Qiang Zhang, Robert L Ferris, David Sidransky, Christine H Chung
Importance: There is a significant need to find biomarkers of response to radiotherapy and cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and biomarkers that predict altered immunity, thereby enabling personalized treatment. Objectives: To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)-variant, a germline mutation in a microRNA-binding site in KRAS, is a predictive biomarker of cetuximab response and altered immunity in the setting of radiotherapy and cisplatin treatment and to evaluate the interaction of the KRAS-variant with p16 status and blood-based transforming growth factor β1 (TGF-β1)...
December 22, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/28006053/cetuximab-and-radiotherapy-in-laryngeal-preservanion
#13
Luca D'Ascanio, Giampietro Ricci, Fabio Piazza
No abstract text is available yet for this article.
December 22, 2016: JAMA Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/28006051/cetuximab-and-radiotherapy-in-laryngeal-preservanion-reply
#14
James A Bonner, Steve Chin, Sharon Spencer
No abstract text is available yet for this article.
December 22, 2016: JAMA Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/27997054/stereotactic-body-radiotherapy-for-recurrent-head-and-neck-cancer-a-critical-review
#15
REVIEW
Sujith Baliga, Rafi Kabarriti, Nitin Ohri, Hilda Haynes-Lewis, Ravindra Yaparpalvi, Shalom Kalnicki, Madhur K Garg
The management of patients with recurrent head and neck cancers remains a challenging clinical dilemma. Concerns over toxicity with re-irradiation have limited its use in the clinical setting. Stereotactic Body Radiation Therapy (SBRT) has emerged as a highly conformal and precise type of radiotherapy and has the advantage of sparing normal tissue. Although SBRT is an attractive treatment modality, its use in the clinic is limited, given the technically challenging nature of the procedure. In this review, we attempt to provide a comprehensive overview of the role of re-irradiation in patients with recurrent head and neck cancers, with particular attention to the advent of SBRT and its use with systemic therapies such as cetuximab...
December 20, 2016: Head & Neck
https://www.readbyqxmd.com/read/27986347/subgroup-analysis-according-to-human-papillomavirus-status-and-tumor-site-of-a-randomized-phase-ii-trial-comparing-cetuximab-and-cisplatin-combined-with-radiation-therapy-for-locally-advanced-head-and-neck-cancer
#16
Michela Buglione, Marta Maddalo, Renzo Corvò, Luigi Pirtoli, Fabiola Paiar, Luciana Lastrucci, Marco Stefanacci, Liliana Belgioia, Monica Crociani, Stefania Vecchio, Pierluigi Bonomo, Silvia Bertocci, Paolo Borghetti, Nadia Pasinetti, Luca Triggiani, Loredana Costa, Sandro Tonoli, Salvatore Grisanti, Stefano Maria Magrini
PURPOSE: We report a subgroup analysis primarily focused on human papillomavirus (HPV)-related oropharyngeal cancer (OPC) from the Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (CTXMAB+RT; ClinicalTrials.gov identifier NCT01216020) trial comparing radiation therapy with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line treatment of locally advanced head and neck cancer. METHODS AND MATERIALS: The data from all the patients in the CTXMAB+RT trial were reviewed and separately analyzed in 3 groups: p16-positive OPC, p16-negative OPC, and all other cancer sites...
March 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27984656/the-toxicity-and-efficacy-of-concomitant-chemoradiotherapy-in-patients-aged-70-years-and-older-with-oropharyngeal-carcinoma-in-the-intensity-modulated-radiotherapy-era
#17
Zachary S Zumsteg, Benjamin H Lok, Allen S Ho, Esther Drill, Zhigang Zhang, Nadeem Riaz, Stephen L Shiao, Jennifer Ma, Sean M McBride, C Jillian Tsai, Shrujal S Baxi, Eric J Sherman, Nancy Y Lee
BACKGROUND: Despite controversy surrounding its benefit, the use of concomitant chemoradiotherapy (CCRT) in patients with oropharyngeal squamous cell carcinoma (OPSCC) who are aged > 70 years is increasing. However, to the authors' knowledge, few studies to date have compared the outcomes of different systemic treatments in this population. METHODS: Records from 74 patients aged ≥ 70 years with stage III to stage IVB OPSCC who were undergoing CCRT from 2002 to 2013 at a single institution were reviewed...
December 16, 2016: Cancer
https://www.readbyqxmd.com/read/27974693/induction-chemotherapy-followed-by-concurrent-chemoradiation-and-nimotuzumab-for-locoregionally-advanced-nasopharyngeal-carcinoma-preliminary-results-from-a-phase-ii-clinical-trial
#18
Jian-Feng Huang, Fu-Zheng Zhang, Qin-Zhou Zou, Le-Yuan Zhou, Bo Yang, Jian-Jun Chu, Jia-Hua Yu, Hao-Wen Zhang, Xiao-Peng Yuan, Guo-Mei Tai, Fen-Ju Liu, C-M Charlie Ma
Overexpression of epidermal growth factor receptor can be found in more than 80% of patients with locoregionally advanced nasopharyngeal carcinoma and is associated with shorter survival. In this work, we evaluated the feasibility of adding nimotuzumab to chemoradiation in locoregionally advanced nasopharyngeal carcinoma. Twenty-three patients with clinically staged T3-4 or any node-positive disease were enrolled. They were scheduled to receive one cycle of induction chemotherapy followed by intensity-modulated radiotherapy, weekly administration of nimotuzumab and concurrent chemotherapy...
January 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/27959944/bemer-electromagnetic-field-therapy-reduces-cancer-cell-radioresistance-by-enhanced-ros-formation-and-induced-dna-damage
#19
Katja Storch, Ellen Dickreuter, Anna Artati, Jerzy Adamski, Nils Cordes
Each year more than 450,000 Germans are expected to be diagnosed with cancer subsequently receiving standard multimodal therapies including surgery, chemotherapy and radiotherapy. On top, molecular-targeted agents are increasingly administered. Owing to intrinsic and acquired resistance to these therapeutic approaches, both the better molecular understanding of tumor biology and the consideration of alternative and complementary therapeutic support are warranted and open up broader and novel possibilities for therapy personalization...
2016: PloS One
https://www.readbyqxmd.com/read/27938998/epidermal-growth-factor-receptor-egfr-pathway-polymorphisms-as-predictive-markers-of-cetuximab-toxicity-in-locally-advanced-head-and-neck-squamous-cell-carcinoma-hnscc-in-a-spanish-population
#20
J Fernández-Mateos, R Seijas-Tamayo, R Mesía, M Taberna, M Pastor Borgoñón, E Pérez-Ruiz, J C Adansa Klain, S Vázquez Fernández, E Del Barco Morillo, A Lozano, R González Sarmiento, J J Cruz-Hernández
OBJECTIVES: To examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab. MATERIAL AND METHODS: Multicenter, retrospective, observational pilot study which included 110 patients with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages (III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003 and 2013...
December 2016: Oral Oncology
keyword
keyword
104263
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"